Fresenius Kabi Pharmaceuticals Holding, Inc. Announces Filing of Form 10-K
24 Februar 2010 - 2:08AM
Business Wire
Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ)
announced today that it has filed its Form 10-K with the Securities
and Exchange Commission. Fresenius Kabi Pharmaceuticals Holding,
Inc. acquired APP Pharmaceuticals, Inc., on September 10, 2008. The
Form 10-K details the Company’s completed audited financial
statements for the fiscal year ending December 31, 2009.
The Form 10-K has been posted to APP’s Web site at
www.APPpharma.com and is also available at the Securities and
Exchange Commission’s Web site at www.SEC.gov.
About Fresenius Kabi Pharmaceuticals Holding, Inc. / APP
Pharmaceuticals, Inc.
Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned
subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc.
on September 10, 2008. APP Pharmaceuticals, Inc. is a
fully-integrated pharmaceutical company that develops, manufactures
and markets injectable pharmaceutical products with a primary focus
on the oncology, anti-infective, anesthetic/analgesic and critical
care markets. The company offers one of the most comprehensive
product portfolios used in hospitals, long-term care facilities,
alternate care sites and clinics within North America and
manufactures a comprehensive range of dosage formulations. For more
information about APP Pharmaceuticals, Inc., please visit the
company’s Web site at www.APPpharma.com.
About Fresenius Kabi AG
Fresenius Kabi AG is the leader in infusion therapy and clinical
nutrition in Europe and in its most important countries of Latin
America and Asia Pacific. Fresenius Kabi’s core product range
includes infusion solutions for fluid substitution, blood volume
expansion, I.V. drugs and parenteral nutrition, as well as products
for enteral nutrition. Furthermore, the company provides concepts
for ambulatory health care and is focused on managing and providing
home therapies. With the philosophy “Caring for life” and a
comprehensive product portfolio, the company aims at improving the
quality of life of patients all over the world. In 2008, Fresenius
Kabi achieved sales of EUR 2,495 million and an operating profit of
EUR 443 million. For more information visit the company’s Web site
at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary
of Fresenius SE. Fresenius SE is a health care group with
international operations, providing products and services for
dialysis, hospital and outpatient medical care. In 2008, group
sales were approximately EUR 12.3 billion. For more information
visit the company’s Web site at www.fresenius.com.
Forward-Looking Statement
The statements contained in this news release that are not
purely historical are forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements in this news release include statements
regarding our expectations, beliefs, hopes, goals, intentions,
initiatives or strategies, including statements regarding the
demand, supply and distribution of our products. Because these
forward-looking statements involve risks and uncertainties, there
are important factors that could cause actual results to differ
materially from those in the forward-looking statements. Additional
relevant information concerning risks are discussed under the
headings “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” in the Fresenius
Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending
December 31, 2009 and other documents the company has filed with
the Securities and Exchange Commission.
The information contained in this news release is as of the date
of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does
not assume any obligation to update or revise these forward-looking
statements to conform the statement to actual results, new
information, developments or changes in the Company’s
expectations.
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ:APCVZ)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Fresenius Kabi Pharmaceuticals Holding - Contingent Value Rights (MM) (NASDAQ:APCVZ)
Historical Stock Chart
Von Mai 2023 bis Mai 2024